Nyxoah S.A. (NYXH) Financial Analysis & Valuation | Quarter Chart
Nyxoah S.A. (NYXH)
NYXHPrice: $3.28
Fair Value: 🔒
🔒score
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.... more
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solut... more
Description
Shares
| Market Cap | $122.49M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Instruments & Supplies |
| Country | BE | CEO | Olivier Taelman |
| IPO Date | 2021-04-28 | CAGR | — |
| Employees | 183 | Website | www.nyxoah.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NYXH chart loading...
Fundamentals
Technicals
| Enterprise Value | $101.23M | P/E Ratio | -1.19 |
| Forward P/E | -2.54 | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-2.76 | EPS Growth 1Y | 29.48% |
| EPS Growth 3Y | 140.86% | EPS Growth 5Y | 467.95% |
| Revenue Growth 1Y | 10.96% | Gross Margin | 0.64% |
| Operating Margin | -14.75% | Profit Margin | -14.85% |
| ROE | -1.01% | ROA | -0.89% |
| ROCE | -1.14% | Current Ratio | 1.7 |
| Quick Ratio | 1.41 | Cash Ratio | 0.52 |
| Debt/Equity | 0.42 | Interest Coverage | -43.66 |
| Altman Z Score | -5.2 | Piotroski Score | 3 |